FI934919A0 - Avgivningssystem med kontrollerad, foerlaengd frigivning Foer roekavvaenjning - Google Patents

Avgivningssystem med kontrollerad, foerlaengd frigivning Foer roekavvaenjning

Info

Publication number
FI934919A0
FI934919A0 FI934919A FI934919A FI934919A0 FI 934919 A0 FI934919 A0 FI 934919A0 FI 934919 A FI934919 A FI 934919A FI 934919 A FI934919 A FI 934919A FI 934919 A0 FI934919 A0 FI 934919A0
Authority
FI
Finland
Prior art keywords
roekavvaenjning
kontrollerad
frigivning
foerlaengd
avgivningssystem
Prior art date
Application number
FI934919A
Other languages
Finnish (fi)
Other versions
FI934919A (en
Inventor
Judith A Kitchell
Indu A Muni
Yvonne N Boyer
Original Assignee
Dynagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynagen Inc filed Critical Dynagen Inc
Publication of FI934919A0 publication Critical patent/FI934919A0/en
Publication of FI934919A publication Critical patent/FI934919A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009Sachets, pouches characterised by the material or function of the envelope

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FI934919A 1991-05-07 1993-11-05 ADJUSTMENT OF THE CONTROL SYSTEM FI934919A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69663791A 1991-05-07 1991-05-07
PCT/US1992/003860 WO1992019241A1 (en) 1991-05-07 1992-05-07 A controlled, sustained release delivery system for smoking cessation

Publications (2)

Publication Number Publication Date
FI934919A0 true FI934919A0 (en) 1993-11-05
FI934919A FI934919A (en) 1993-12-17

Family

ID=24797928

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934919A FI934919A (en) 1991-05-07 1993-11-05 ADJUSTMENT OF THE CONTROL SYSTEM

Country Status (8)

Country Link
EP (1) EP0720478A1 (en)
JP (1) JPH06507416A (en)
AU (2) AU2154892A (en)
CA (1) CA2102507A1 (en)
FI (1) FI934919A (en)
HU (1) HUT69390A (en)
NO (1) NO933971L (en)
WO (2) WO1992019226A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
ZA932273B (en) * 1992-03-30 1993-11-26 Alza Corp Additives for bioerodible polymers to regulate degradation
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5612357A (en) * 1992-05-18 1997-03-18 Pharmaco Behavioral Associates, Inc. Use of cotinine to assist in the cessation of tobacco smoking
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
SE519940C2 (en) * 1994-06-03 2003-04-29 Carl Dahlborn Ab Implantable device
ATE214276T1 (en) * 1994-09-19 2002-03-15 Du Pont Pharm Co COMPOSITIONS OF OPIOID ANTAGONISTS WITH SELECTIVE SEROTONIN UPtake INHIBITORS, FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU748804B2 (en) * 1995-07-20 2002-06-13 Smithkline Beecham Plc Paroxetine controlled release compositions
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
DE19642043A1 (en) * 1995-10-23 1997-04-24 Hexal Ag Transdermal therapeutic system for treating drug dependency
AU3601897A (en) * 1996-07-15 1998-02-09 Alza Corporation Novel formulations for the administration of fluoxetine
EP1393724B1 (en) * 1996-07-15 2006-04-05 Alza Corporation Novel formulations for the transdermal administration of fluoxetine
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
WO1998053815A1 (en) * 1997-05-30 1998-12-03 Minnesota Mining And Manufacturing Company Transdermal drug delivery device for the delivery of tropisetron or granisetron
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
ES2141024B1 (en) * 1997-10-03 2000-10-16 Manzanares Jesus Mari Gonzalez PREPARED FOR ANTHINYCOTINIC ACTION.
DE19746191C2 (en) 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Method of using an active ingredient-containing patch to combat or alleviate addiction
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
CA2318738A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
CA2318921A1 (en) 1998-01-29 1999-08-05 John R. Mccullough Pharmacological uses of optically pure (+)-bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
ATE531374T1 (en) 2004-04-15 2011-11-15 Alkermes Inc DELAYED RELEASE POLYMER BASED DEVICE
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
PT2157967E (en) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
KR101823699B1 (en) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR102574993B1 (en) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4917676A (en) * 1986-11-20 1990-04-17 Ciba-Geigy Corporation User-activated transdermal therapeutic system
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
CA1273878A (en) * 1987-01-15 1990-09-11 Richard Philip Moody Nicotine-containing preparation for transdermal administration
JP2677371B2 (en) * 1988-01-30 1997-11-17 帝國製薬株式会社 Hydrous smoking substitute patch
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction

Also Published As

Publication number Publication date
JPH06507416A (en) 1994-08-25
HUT69390A (en) 1995-09-28
WO1992019226A1 (en) 1992-11-12
AU2016092A (en) 1992-12-21
AU657973B2 (en) 1995-03-30
FI934919A (en) 1993-12-17
WO1992019241A1 (en) 1992-11-12
NO933971D0 (en) 1993-11-03
NO933971L (en) 1994-01-07
CA2102507A1 (en) 1992-11-08
EP0720478A1 (en) 1996-07-10
AU2154892A (en) 1992-12-21
HU9303146D0 (en) 1994-01-28

Similar Documents

Publication Publication Date Title
FI934919A0 (en) Avgivningssystem med kontrollerad, foerlaengd frigivning Foer roekavvaenjning
FI920527A0 (en) KRAFTKAELLA MED EN HOEGENERGIFAKTOR.
FI923888A0 (en) TILLSLUTARE MED AUTOMATISK TRYCKUTJAEMNING.
FI921708A (en) STOLSTOPPNING, SPECIELLT FLYGPLANSFAOTOELJ
FI922494A (en) PULVERFORM, ENZYMER INNEHAOLLANDE DISKMEDELSKOMPOSITION FOER AUTOMATISKA DISKMASKINER
FI920718A0 (en) VAETSKEFOERDELARE MED INDRAGET FOERDELNINGSMUNSTYCKE.
FI923987A0 (en) RADIOMOTTAGARE OCH -SAENDARE MED SKILLNADSFUNKTION.
FI921384A0 (en) MED KOMPENSATIONSPRINCIP FUNGERANDE MAGNETKAERNA FOER EN STROEMDETEKTOR.
FI923541A0 (en) SCHABERANORDNING MED SCHABERBALK.
FI920440A0 (en) SQUID-MAETNINGSANORDNING FOERSEDD MED SKYDDSORGAN.
FI922774A0 (en) EFFEKTFAKTORKORRIGERANDE ENSTEGSOMVANDLARE MED EN ISOLERAD UTGAONG.
FI914735A0 (en) MED LEDBOMMAR FOERSEDD ARBETSMASKIN.
FI924196A0 (en) MED FLYTGASBRAENNARE UPPHETTBART RULLAKTIGT TAECKNINGSMATERIAL.
FI922274A0 (en) MED SLAECKNINGSGAS FUNGERANDE FLER- STAELLNINGSVRIDSTAELLARE.
FI922015A0 (en) TELEVISIONSMOTTAGARE FOERSEDD MED DELVIS PASSERAD OLINEAER LUMINANSSIGNALPROSESSOR.
FI921921A0 (en) HYDROCYKLONSEPARATOR MED TURBULENS- SKYDD.
FI912080A0 (en) LAGRINGSLAODA FOERSEDD MED EN GAVELVAEGGEN SLUTANDE GENOMSYNLIG KLAFFSKIVA.
FI920393A0 (en) RADIO- OCH LANDFOERBINDELSETELEFONER MED HANDS-FREE-FUNKTION.
FI924375A0 (en) STIGARROER MED FLYTANDE BRUNNSBETAECKNING.
FI920834A0 (en) MED FUKOS MAERKTA CYTOSTATER.
FI923748A0 (en) STROEMSENSOR FUNGERANDE MED KOMPENSATIONSPRINCIP.
FI921759A (en) LINEAER VISKOELASTISK VATTENHALTIG FLYTANDE DETERGENTKOMPOSITION, SPECIELLT FOER AUTOMATISKA DISKMASKINER
FI920215A (en) ISOLERING MED MYCKET LAOG STELNINGSPUNKT.
FI920262A (en) JODOFORKOMPOSITIONER MED OEKAD STABILITET.
FI920953A0 (en) BELAEGGNINGSKOPP MED TVAO INGAONGAR FOER FIBERBANDKABEL.

Legal Events

Date Code Title Description
FD Application lapsed